IDH1 and glioblastoma: Since IDH1 mutation, MGMT promoter methylation, and CpG island methylation phenotype (CIMP) have been widely used to estimate the effectiveness of radiation and TMZ therapies on GBM patients, we next analyzed the transcription profiling of H2AFJ in these molecular classifications.